Abstract
The unique biological properties of Geminin, particularly as an inhibitor of DNA replication initiation, have been recognized, and this has prompted a number of investigations into this molecule to explore its potential therapeutic as well as diagnostic usefulness. This review summarizes the possibility of Geminin serving as a new molecular target in the development of new anticancer drugs.
Keywords: Geminin, Cdt1, DNA replication, Cancer cell, Peptide
Mini-Reviews in Medicinal Chemistry
Title: Geminin as A Molecular Target for the Development of New Anticancer Drugs
Volume: 6 Issue: 4
Author(s): Kenichi Yoshida
Affiliation:
Keywords: Geminin, Cdt1, DNA replication, Cancer cell, Peptide
Abstract: The unique biological properties of Geminin, particularly as an inhibitor of DNA replication initiation, have been recognized, and this has prompted a number of investigations into this molecule to explore its potential therapeutic as well as diagnostic usefulness. This review summarizes the possibility of Geminin serving as a new molecular target in the development of new anticancer drugs.
Export Options
About this article
Cite this article as:
Yoshida Kenichi, Geminin as A Molecular Target for the Development of New Anticancer Drugs, Mini-Reviews in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/138955706776361411
DOI https://dx.doi.org/10.2174/138955706776361411 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiolabeled Peptides and Proteins in Cancer Therapy
Protein & Peptide Letters Towards the Design of Social Media to Promote Physical Activity
Recent Advances in Communications and Networking Technology (Discontinued) Genetics, Structure, Function, Mode of Actions and Role in Cancer Development of CYP17
Anti-Cancer Agents in Medicinal Chemistry Multimodality Imaging of RNA Interference
Current Medicinal Chemistry An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Editorial [Hot Topic: The Human Microbiome - A Therapeutic Target for Prevention and Treatment of Chronic Disease (Executive Editor: Kieran Tuohy)]
Current Pharmaceutical Design Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Defining Cell Identity by Comprehensive Gene Expression Profiling
Current Medicinal Chemistry Heterocyclic Analogues as Kinase Inhibitors: A Focus Review
Current Topics in Medicinal Chemistry Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer
Current Molecular Medicine The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Molecular Targeted Therapy of Gastrointestinal Stromal Tumors
Current Cancer Drug Targets microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Relationship Between Metal Transcription Factor-1 and Zinc in Resistance to Metals Producing Free Radicals
Current Chemical Biology Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets